Dimerix Investment
Dimerix is adopting a diversified investment approach, targeting a
range of speciality innovative new chemical entities (NCE’s) to treat kidney diseases
Currently the Dimerix business has two distinct opportunities:
1.
DMX-200 for FSGS, which is currently in a fully recruited Phase 3 clinical trial
2.
DMX-652 for acute kidney injury (AKI), which is currently entering a Phase 2 clincial trial
The Dimerix approach to business strategy
- Developing and applying Dimerix proprietary technology and core competencies across kidney disease indications.
- Evaluating other opportunities through mergers, licencing and acquisitions that build the Dimerix pipeline.
- Developing strong proprietary positions through patents to maintain and extend competitive advantages for existing and new drugs.
- Creating a diversified portfolio of products to generate future income streams.
- Build and develop a solid product pipeline that has an attractive projected internal rate of return.
- Establish a culture of shared leadership and accountability.
- Build strong strategic partnerships which will enhance expertise and / or mitigate the capital obligations and commercial risk.
